

Assess Cannabis-Based Medicine and Product Funding Requests v5.0



Summary

Objective

To ensure recovery team members consistently access Recovery Support in order to make accurate decisions on funding requests for cannabis-based medicine or products. In all cases written advice from a Pharmaceutical Advisor is necessary.

Background

There is increasing demand for ACC to fund cannabis-based medicines and products, and there needs to be a consistent process for recovery team members to follow.

Owner Stafford Thompson

Expert Jamie Macniven

Procedure

1.0 Review claim documents


Recovery Assistant, Recovery Coordinator, Recovery Partner, Treatment and Support Assessor

- a** Establish that there is a written request to fund a cannabis-based medicine or product.

NOTE Which medicines or products are cannabis-based?

Current examples include Sativex, Tilray, Endocan, and Swift. However, there are many more cannabis-based products coming onto the NZ market. Some of these products may also contain THC (tetrahydrocannabinol; the principal psychoactive component of cannabis).

- b** Ensure that the prescriber has completed an ACC1171 - Request for pharmaceutical funding.

 ACC1171 Request for pharmaceutical funding form

NOTE What if the prescriber has not completed this form?

Check whether the ACC1171 is on file elsewhere. If so, proceed to 1c. If not, send the requestor the ACC1171 template and ask that they complete this and return the form in order for the request to be considered.

- c** Ensure that part C of the ACC1171 form has been completed by a medical specialist who is overseeing prescribing.

NOTE What if this section is incomplete, or has been completed by someone other than the medical specialist overseeing prescribing?

Send the form back to the prescriber and request that part C is completed within 20 working days. If no response is received within this timeframe, inform the provider that the request cannot be considered without the required information. If no further information is provided at that time, decline the request.

- d** Collate relevant clinical documents, such as any up to date clinical reports and/or GP notes, and social rehabilitation or needs assessment reports, showing clinical and rehabilitation outcomes to date.

2.0 Seek Internal Guidance

Recovery Assistant, Recovery Coordinator, Recovery Partner, Treatment and Support Assessor

- a** Request written advice from the National Pharmaceutical Advisory team.

NOTE How do I obtain advice from a Pharmaceutical Advisor?

Follow the NGCM Seek Internal Guidance process. Specify in the internal guidance eform, 'Is this treatment necessary and appropriate?'.

NOTE What if the request is to fund a renewal which has been directed by Review?

Written advice from a Pharmaceutical Advisor is still required.



PROCESS

Seek Internal Guidance

Recovery Assistant, Recovery Coordinator, Recovery Partner

3.0 Issue recovery decision

Recovery Assistant, Recovery Coordinator, Recovery Partner, Treatment and Support Assessor

- a** On receipt of internal guidance, issue a recovery decision.



PROCESS

Issue Recovery Decision

UNASSIGNED

Summary

Objective

We do not normally pay for products available for use in the community that contain controlled drugs, such as cannabis and ketamine. This is because of the:

- lack of high-quality clinical evidence that supports their use
- wide availability of other pharmacological and non-pharmacological interventions to achieve rehabilitation outcomes
- unapproved/non regulated therapeutic use (ie. Medsafe has not registered and/or approved the product or indication for use)

Owner s 9(2)(g)(ii)

Expert s 9(2)(g)(ii)

Policy

1.0 Rules

a You must refer requests for contributions towards costs of any of the above preparations to the National Pharmaceutical Advisory team Department for pharmaceutical advisor assessment and comment.

b For all pharmaceutical referrals, complete the Clinical Advice Referral form (ACC001) and attach to the Recommended Pharmaceutical item task.



Seeking Internal Guidance

<https://au.promapp.com/accnz/Process/d1385da6-a1b5-43ac-93ad-91052121a62e?force=True>

2.0 Other Information

a If referring a ketamine funding request, please ensure that the clinician provides evidence as outlined in the Ketamine - Cover and Entitlement document



Ketamine - cover and entitlement

http://thesauce/intra/groups/intranet_content/documents/resources_and_tools/ts096330.pdf